[Evaluation of the efficacy of azithromycin and pyrimethamine, for treatment of experimental infection of mice with Toxoplasma gondii cystogenic strain].

The efficacy of prolonged administration of azithromycin and pyrimethamine was evaluated in mice experimentally infected with cystogenic strain of Toxoplasma gondii. The animals were intraperitoneally inoculated with one cyst of T. gondii and after 20 days were allocated into four groups: GI, infected without treatment; GII, infected and treated with the association of pyrimethamine (12.5 mg/kg/day) and azithromycin (100 mg/kg/day); GIII, infected and treated with the same dose of pyrimethamine; and GIV, infected and treated in the same way with azithromycin. The oral treatment lasted 120 days, after this period all the animals were sacrificed and the count of cysts in the brain was done. The association of both drugs provided the best results, by diminishing the cyst count in the brain of the animals treated in this way.

[1]  F. Verbraak,et al.  A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis. , 2002, American journal of ophthalmology.

[2]  F. Derouin.  Anti-toxoplasmosis drugs. , 2001, Current opinion in investigational drugs.

[3]  V. A. Neto,et al.  Avaliação da eficácia da azitromicina e da pirimetamina, usadas isolada ou associadamente, no tratamento de infecção experimental de camundongos pelo Toxoplasma gondii , 1999 .

[4]  F. Derouin.  [New pathogens and mode of action of azithromycin: Toxoplasma gondii]. , 1995, Pathologie-biologie.

[5]  P. Piguet,et al.  Evaluation of the efficacy of prolonged administration of azithromycin in a murine model of chronic toxoplasmosis. , 1994, The Journal of antimicrobial chemotherapy.

[6]  E. Godofsky.  Treatment of presumed cerebral toxoplasmosis with azithromycin. , 1994, The New England journal of medicine.

[7]  M. Gardner,et al.  Pharmacokinetics of azithromycin in pediatric patients after oral administration of multiple doses of suspension , 1993, Antimicrobial Agents and Chemotherapy.

[8]  R. Brettle,et al.  Azithromycin for cerebral toxoplasmosis in AIDS , 1993, The Lancet.

[9]  M. Sande,et al.  Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome. , 1992, The New England journal of medicine.

[10]  B. Luft,et al.  Toxoplasmic encephalitis in AIDS. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  L. Perrin,et al.  Toxoplasma Encephalitis in Patients with the Acquired Immunodeficiency Syndrome , 1992, Medicine.

[12]  F. Derouin,et al.  Synergistic activity of azithromycin and pyrimethamine or sulfadiazine in acute experimental toxoplasmosis , 1992, Antimicrobial Agents and Chemotherapy.

[13]  B. Currie,et al.  Azithromycin for cerebral toxoplasmosis , 1992, The Lancet.

[14]  N Clumeck,et al.  Treatment of Toxoplasmic Encephalitis in Patients with AIDS , 1992, Annals of Internal Medicine.

[15]  J. Remington,et al.  Azithromycin, a macrolide antibiotic with potent activity against Toxoplasma gondii , 1988, Antimicrobial Agents and Chemotherapy.